Patient recruitment hindered by mistrust of clinical trials

By Nick Taylor

- Last updated on GMT

Related tags: Clinical trial

Mistrust of clinical trials and poor patient engagement is limiting recruitment into US studies, an IOM forum heard.

At the conference, hosted by the Institute of Medicine (IOM)​, regulators, industry and others discussed how poor patient engagement is hindering clinical trial recruitment and retention.

Richard Murray, head of the global center for scientific affairs at Merck & Co, said public mistrust of clinical trials, science, and the motives of the pharmaceutical industry is limiting recruitment.

Murray also said the relatively high standard of care in the US means many patients have already had some type of treatment. In search of treatment naïve patients contract research organisations (CROs) and biopharm and have entered new markets, but this could create further trust problems.

This trend could be perceived as posing ethical problems, especially if the treatments being tested are not available in the overseas patients’ own country​”, the IOM quotes Murray as having said.

Reversing the trend

Building trust through community outreach and education is one of seven elements of a successful clinical trial, Juan Lertora, director clinical pharmacology program at the NIH (US National Institutes of Health) Clinical Center, said.

A NIH initiative is focused on improving recruitment through better patient engagement. “The Clinical Center will participate in an aggressive campaign to engage the public in the clinical research process​”, John Gallin, director of the NIH Clinical Center, wrote in a Nature Medicine​ article​.

Success stories

Presenters at the IOM conference highlighted several success stories that suggest the public want to take part in clinical trials. Many of these came from patient groups and consumer-oriented organisations that take a different approach to clinical trial engagement.

Use of a web interface to provide registrants with instant feedback on survey questions is in striking contrast to the lack of information that participants in conventional trials receive​”, the IOM quotes Nancy Sung, senior program officer at Burroughs Wellcome Fund, as having said.

Related news

Show more

Related products

show more

Using SDTM, ADaM, and SEND

Using SDTM, ADaM, and SEND

Formedix | 09-Nov-2022 | Technical / White Paper

This article gives an overview of SDTM, ADaM, SEND and ARM, and discusses how these CDISC standards fit in with the wider clinical trial process, and how...

How to design an effective CRF

How to design an effective CRF

Formedix | 10-Oct-2022 | Technical / White Paper

CRFs and eCRFs are used for gathering patient data during clinical trials. They play a crucial role in helping to assess the safety and efficacy of clinical...

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Because When It's On the Line... Capability Matters.

Because When It's On the Line... Capability Matters.

Baxter BioPharma Solutions | 01-Oct-2022 | Product Brochure

Baxter’s BioPharma Solutions business supports leading pharmaceutical companies in meeting their commercialization objectives by providing scientific expertise,...

Related suppliers

Follow us

Products

View more

Webinars